Office of Research & Development

Registry of In Process and Executed VA CRADAs

To track CRADAs and to create an educational resource, the Technology Transfer Program (TTP) requires VA Medical Centers (VAMCs) or Non-Profit Corporations (NPCs) to register CT CRADAs through the TTP website.

Upon initiating negotiations, please go the website: (This link is available on the intranet only. If you have intranet access, copy and paste the URL into your browser.) (You will need a User ID and password and a VA) website and fill out as much as possible on the eCRADA Registry. If your NPC/VAMC does not have a User ID and password, or you forgot it, please contact Noahline Stuart at to retrieve it. NOTE: This is an intranet and not the internet site.

When the CRADA has been negotiated (signed and completed), you must upload the CRADA to its respective file on the eCRADA Registry. If you choose to wait until the CRADA is negotiated to upload it, then you can do so. If you have any other questions, please contact Noahline Stuart.

Master CRADAs

VA has Master template CRADAs where no additional legal or TTP review of the CRADA body is needed. Unless otherwise noted, these agreements are for Phase 3,4 clinical trials in which the collaborator has provided the protocol for the study. They may only be used for the specific clinical trial phase shown . Currently the VA has not negotiated any Master templates for the Basic, Principal Investigator, Data Collection or Investigational Device CRADAs.

A list of the approved Master template CRADAs are shown below. Please email Noahline Stuart ( for a copy. For questions about any future master agreements please contact Ken Levin (

  • Amgen (Phase 1-3, Phase 4 updated 9/2/2014)
  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Forest Research
  • Genentech
  • Glaxo Smith Kline (GSK)- Phase 3,4, Study Start Up Agreement
  • Merck-Phase 1,2 and Phase 3,4
  • Novartis-Phase 2,3 and Phase 3,4
  • OncoGenex
  • Pfizer
  • Roche
  • Sanofi-Aventis-Phase 2,3 and Phase 3,4
  • Sucampo
  • Watson Pharmaceuticals